Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Swiss Hemophilia Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02512250
Recruitment Status : Recruiting
First Posted : July 30, 2015
Last Update Posted : April 28, 2021
Sponsor:
Information provided by (Responsible Party):
Swiss Hemophilia Network

Brief Summary:
The Swiss Hemophilia Registry will collect data on the prophylactic and therapeutic use of factor concentrates in patients with hemophilia and other severe bleeding disorders in Switzerland.

Condition or disease Intervention/treatment
Hemophilia and Other Severe Bleeding Disorders Other: Registry

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 900 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 10 Years
Study Start Date : May 2015
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Number of incidence of disease and inhibitor development [ Time Frame: 1 year ]
  2. Amount of factor concentrate consumption [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with hemophilia and other severe bleeding disorders
Criteria

Inclusion Criteria:

Diagnosis of hemophilia or other severe bleeding disorders. Signed inform consent

Exclusion Criteria:

None


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02512250


Contacts
Layout table for location contacts
Contact: Manuela Albisetti, MD +41 44 266 71 38 manuela.albisetti@kispi.uzh.ch

Locations
Show Show 20 study locations
Sponsors and Collaborators
Swiss Hemophilia Network
Additional Information:

Layout table for additonal information
Responsible Party: Swiss Hemophilia Network
ClinicalTrials.gov Identifier: NCT02512250    
Other Study ID Numbers: 2014-0667
First Posted: July 30, 2015    Key Record Dates
Last Update Posted: April 28, 2021
Last Verified: April 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemostatic Disorders
Hemophilia A
Blood Coagulation Disorders
Blood Coagulation Disorders, Inherited
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Vascular Diseases
Cardiovascular Diseases